Showing 2775 results
-
Press release /Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development and review of treatments for serious…
-
Press release /Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands…
-
Press release /In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI…
-
Press release /New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern USPurpose-built facility will strengthen Novartis RLT…
-
Biography /
-
Story /How shared decision-making can support living well from the start with chronic myeloid leukemia
-
Story /Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support inclusive, resilient healthcare systems worldwide.
-
Story /Our innovations matter only when they reach the people who need them. Yet millions live with heart disease or cancer without knowing it or have limited access to care – especially those in low-income, rural or other hard-to-reach communities.
-
Press release /Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,…